Malignant Pleural Mesothelioma - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 152 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Malignant Pleural Mesothelioma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Malignant Pleural Mesothelioma - Pipeline Review, H2 2014', provides an overview of the Malignant Pleural Mesothelioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Malignant Pleural Mesothelioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Malignant Pleural Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Malignant Pleural Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Malignant Pleural Mesothelioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Malignant Pleural Mesothelioma Overview 9
Therapeutics Development 10
Pipeline Products for Malignant Pleural Mesothelioma - Overview 10
Pipeline Products for Malignant Pleural Mesothelioma - Comparative Analysis 11
Malignant Pleural Mesothelioma - Therapeutics under Development by Companies 12
Malignant Pleural Mesothelioma - Therapeutics under Investigation by Universities/Institutes 14
Malignant Pleural Mesothelioma - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Malignant Pleural Mesothelioma - Products under Development by Companies 17
Malignant Pleural Mesothelioma - Products under Investigation by Universities/Institutes 18
Malignant Pleural Mesothelioma - Companies Involved in Therapeutics Development 19
Boehringer Ingelheim GmbH 19
Biogen Idec Inc. 20
GlaxoSmithKline plc 21
MedImmune, LLC 22
Oxford BioMedica plc 23
Novartis AG 24
Pfizer Inc. 25
Aduro BioTech, Inc. 26
Bionomics Limited 27
Synta Pharmaceuticals Corp. 28
Morphotek, Inc. 29
Virttu Biologics Limited 30
Five Prime Therapeutics, Inc. 31
CanBas Co., Ltd. 32
MolMed S.p.A. 33
Pharma Mar, S.A. 34
Genelux Corporation 35
Polaris Group 36
Verastem, Inc. 37
Malignant Pleural Mesothelioma - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Target 40
Assessment by Mechanism of Action 43
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
tremelimumab - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
TroVax - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
NGR-hTNF - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
nintedanib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
dovitinib lactate - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
amatuximab - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CBP-501 + [cisplatin] + [pemetrexed disodium] - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
pegargiminase - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
defactinib - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
PF-03446962 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
BNC-105P - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
trabectedin - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ganetespib - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
HSV-1716 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
FP-1039 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
BG-00001 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
GLONC-1 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
GSK-2256098 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
CRS-207 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Cell Therapy for Malignant Pleural Mesothelioma - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Cell Therapy 1 for Oncology - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
MV-NIS Vaccine - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
SS1(dsFv)-PE38 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
MesoCART - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Stem Cell Therapy Targeting TRAIL Receptor for Oncology - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Malignant Pleural Mesothelioma - Recent Pipeline Updates 104
Malignant Pleural Mesothelioma - Dormant Projects 141
Malignant Pleural Mesothelioma - Discontinued Products 142
Malignant Pleural Mesothelioma - Product Development Milestones 143
Featured News & Press Releases 143
Jun 02, 2014: Aduro Announces ASCO Presentation of Promising Results from Phase 1b Clinical trial of its Novel Immunotherapy for the Treatment of Mesothelioma 143
May 15, 2014: MolMed: five studies on investigational therapies NGR-hTNF and TK have been selected for presentation at ASCO 2014 144
May 12, 2014: Verastem Announces Initiation of COMMAND Study in Japan 145
Dec 20, 2013: MolMed expands in Russia the Phase II trial of NGR-hTNF for the first line maintenance treatment of pleural mesothelioma 146
Oct 28, 2013: Polaris Group Announces Positive Results for Phase 2 Study of ADI-PEG 20 in Malignant Pleural Mesothelioma 146
Oct 24, 2013: Verastem Announces Presentations at the 2013 World Conference on Lung Cancer 147
Sep 10, 2013: Verastem Initiates COMMAND: A Registration-Directed Trial of Defactinib in Patients with Mesothelioma 148
Sep 10, 2013: Veristat to Assist on Adaptive Enrichment Trial for Verastem's Defactinib in Mesothelioma 149
Aug 27, 2013: Oncolytic Virus Specialist Virttu Biologics Confirms Treatment of First Cohort of Patients in Phase I/II SEPREHVIR Study in Mesothelioma 149
May 20, 2013: Aduro Announces Poster Presentations Of Phase II Pancreatic Cancer And Phase IB Mesothelioma Clinical Trials At ASCO 150
Appendix 151
Methodology 151
Coverage 151
Secondary Research 151
Primary Research 151
Expert Panel Validation 151
Contact Us 152
Disclaimer 152

List of Tables
Number of Products under Development for Malignant Pleural Mesothelioma, H2 2014 10
Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Malignant Pleural Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H2 2014 19
Malignant Pleural Mesothelioma - Pipeline by Biogen Idec Inc., H2 2014 20
Malignant Pleural Mesothelioma - Pipeline by GlaxoSmithKline plc, H2 2014 21
Malignant Pleural Mesothelioma - Pipeline by MedImmune, LLC, H2 2014 22
Malignant Pleural Mesothelioma - Pipeline by Oxford BioMedica plc, H2 2014 23
Malignant Pleural Mesothelioma - Pipeline by Novartis AG, H2 2014 24
Malignant Pleural Mesothelioma - Pipeline by Pfizer Inc., H2 2014 25
Malignant Pleural Mesothelioma - Pipeline by Aduro BioTech, Inc., H2 2014 26
Malignant Pleural Mesothelioma - Pipeline by Bionomics Limited, H2 2014 27
Malignant Pleural Mesothelioma - Pipeline by Synta Pharmaceuticals Corp., H2 2014 28
Malignant Pleural Mesothelioma - Pipeline by Morphotek, Inc., H2 2014 29
Malignant Pleural Mesothelioma - Pipeline by Virttu Biologics Limited., H2 2014 30
Malignant Pleural Mesothelioma - Pipeline by Five Prime Therapeutics, Inc., H2 2014 31
Malignant Pleural Mesothelioma - Pipeline by CanBas Co., Ltd., H2 2014 32
Malignant Pleural Mesothelioma - Pipeline by MolMed S.p.A., H2 2014 33
Malignant Pleural Mesothelioma - Pipeline by Pharma Mar, S.A., H2 2014 34
Malignant Pleural Mesothelioma - Pipeline by Genelux Corporation, H2 2014 35
Malignant Pleural Mesothelioma - Pipeline by Polaris Group, H2 2014 36
Malignant Pleural Mesothelioma - Pipeline by Verastem, Inc., H2 2014 37
Assessment by Monotherapy Products, H2 2014 38
Assessment by Combination Products, H2 2014 39
Number of Products by Stage and Target, H2 2014 42
Number of Products by Stage and Mechanism of Action, H2 2014 45
Number of Products by Stage and Route of Administration, H2 2014 47
Number of Products by Stage and Molecule Type, H2 2014 49
Malignant Pleural Mesothelioma Therapeutics - Recent Pipeline Updates, H2 2014 104
Malignant Pleural Mesothelioma - Dormant Projects, H2 2014 141
Malignant Pleural Mesothelioma - Discontinued Products, H2 2014 142